Audrey’s Life Science Meeting Picks for October-November 2010 Complimentary Service of AudreysNetwork.com (Oct. 9, 2010 Edition)

*********************************************************** Bio2DeviceGroup, Tuesday Evening, Tuesday, Oct. 12, 2010

Topic: “Gene Therapy: The Next Generation Cancer Therapy” Speaker: Jeff Galvin, CEO, American Gene Technologies Date and Time: Tuesday Evening, Oct. 12, 2010 Location: Wilson Sonsini Goodrich & Rosati-- 650 Page Mill Road, Palo Alto , CA 94306 Register at www.bio2devicegroup.org week prior to meeting

Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins

Topic Description

Jeff will speak about the work of his company American Gene Technologies (AGTII) in developing potentially improved cancer therapies with higher efficacy than currently available drug treatments. AGTII was founded in 2007 to develop bio-safe, high- efficiency, multi-gene vectors for human gene delivery, in-vivo. AGTII’s products provide a method for the clinical delivery of gene therapy for the treatment of cancers, autosomal disorders, stem cell therapies, and cosmetic applications.

Speaker Bio Jeffrey A. Galvin, CEO, Inventor, and Co-Founder of AGTII earned his degree in economics from Harvard College in 1981. He has over 30 years of business and entrepreneurial experience in Silicon Valley including founder or executive positions at several startups that were taken public and/or sold to public companies -- including a company that provided the market-dominant quality control software for linear accelerators in cancer clinics which was sold to Varian, Inc (NYSE:VAR). In 2007 Mr. Galvin founded an angel investment company which provided the startup capital for AGTII.

******************************************************** Deloitte Recap’s Free Webinar, Tuesday Morning, Oct. 12, 2010

Topic: “Development and Commercialization Diligence in Biopharma Alliances” Join Recap's free, live webinar Date and Time: October 12, 2010,10:00-11:00 AM Pacific / 1:00-2:00 PM Eastern Register to attend today! http://www.recap.com/882575E5007F1AA1/w_WebinarReg?OpenForm&U=502ED6EA81 87E6CF88257752000BEBC1

Topic Description Is there more to development and commercialization diligence in biopharma alliances than "use reasonable efforts"? Should there be? Join us on October 12 to explore this issue. The business terms of biopharma alliances have changed substantially over the past decade with respect to financial payments, risk sharing and dev elopment options. However, the diligence standards for clinical development, regulatory approval and commercialization are generally unchanged when big pharma is the licensee, and only occasionally more specific when specialty pharma in-licenses a compound.

As more products come to market through alliances, should there be a tightening of performance requirements with respect to:

 Clinical development timetables  Development expenditures  Minimum annual sales  Commercial expenditures

We will survey recent biopharma alliances, describe and discuss novel approaches, and debate the merits and drawbacks of such provisions.

Who should attend:

 Business development  Biopharma corporate executives  VCs and investment banks  CFOs and financial executives  Legal

Can't attend live? Register to receive the recorded webinar and accompanying slides. ******************************************************** SF AWIS, Wednesday Evening, Oct. 13, 2010

Event: “Social Networking” Date and Time: Wednesday, October 13th, 2010 Location: Bissap Baobab, 2323 Mission Street, San Francisco, COST: FREE All professionals in the sciences, students, and friends are welcome. For additional information check http://www.sfawis.com/

******************************************************************* NorCal BioPharmaPM, Thursday Evening, Oct. 14, 2010

Topic: "Perspectives on the Practice of Project Management in Biotechnology over the Last 15 years" Speakers: Rajendra Mohabir, Ph.D and Timothy Yang, PMP Date: Thursday October 14, 2010, 6:00-9:30 PM Agenda 6:00 pm - 7:00 pm Networking 7:00 pm - 8:00 pm Dinner 8:00 pm - 9:30 pm Presentation Location: Hilton Garden Inn MAP, 670 Gateway Boulevard, South San Francisco Cost: $45 (+ nominal service fee), please RSVP on Eventbrite to register

Topic Description Please join us for an interactive discussion to share best industry practices for Project Management in Biotechnology. The keynote speakers have 40 years of combined experience in instituting Project Management Offices and refining the practice of Project Management from early to commercial development of global programs. The presenters will speak about the following topics, and offer counter perspectives to:  Team Models  Roles and Responsibilities  Necessary Background for a Successful Project Manager  Value of Project Management

Cuisine Offerings Networking Beverage Service - Complimentary sodas, bottled water, juices, iced tea, and coffee & tea - Cash bar service Buffet Dinner Service

Speaker Bios Raj Mohabir has 20 years of industry experience. He started off his career as a Staff Scientist at Syntex Discovery Research. He then held roles of increasing responsibility in project management/team leadership at Roche in Palo Alto, Genentech and Amgen. He also had expanded management responsibility at Amgen where he was Head of Oncology Project Management. He returned to Roche Palo Alto in 2008, where he was Site Head for Global Project Management. In Q3 2009, he returned to Genentech, where he is currently the Head of Project Management for Genentech Research and Early Development. Raj has a Bachelor’s degree in Microbiology and Immunology from McGill University, a Ph.D. in Pharmacology from Dalhousie University, and completed post-doctoral training in Cardiology at Stanford University School of Medicine.

Tim Yang has worked at Genentech, Inc. for 19 years across multiple functions including Manufacturing, Clinical Research, Commercial and Product Development/Project Management. His current role is as an Associate Director in the Portfolio Management and Operations group, primarily supervising Project Managers. Tim holds a Bachelor’s degree in Evolutionary Biology with a minor in Music Theory and Performance from UC Santa Cruz, and a Master’s degree in Public Administration from the University of San Francisco. He is also PMP certified.

Registration Please RSVP on Eventbrite to secure your reservation. Cash, check or credit cards will be accepted (cash and checks, please tender in person or by mail). Payments must be received by October 12th.

***************************************************

Golden Gate Polymer Forum, Thursday, Oct. 14, 2010

Topic: "Nanobreadboards and Self-Organizing Polymers: An Introduction to (Synthetic) DNA Nanotechnology" Speaker: Rebecca Schulman, Miller Fellow, Department of Physics, University of California, Berkeley,http://www.rschulman.org Date and Time:Thursday, Oct. 14, 6:00 PM social hour, 7:00 PM dinner, 8:00 PM presentation Location: Michael's Restaurant at Shoreline Park, Mountain View (directions below) Dinner Selections: Salmon filet with beurre blanc Chicken Marsala Eggplant Parmigiana Cost: Employed/postdocs: $35 normal registration Unemployed/retired/students: $20 normal registration After deadline: registration not guaranteed, so contact us late fee applies -- $40 regular/employed, $25 unemployed/student/retired Free if you attend just the lectures at 8:00 PM (but please let us know for headcount)

Deadlines for registration: Advance registration ends 5pm Wed. Oct 6. Regular registration ends 5pm Wed. Oct 13. Because we must pay the restaurant for the ordered meal, we must ask no- shows to pay for their reservation. However, penalty-free cancellations are allowed up until the deadline for reservations the day before the event. Location: Address: 2960 N Shoreline Blvd. PLEASE NOTE: we accept cash or checks, but are unable to accept payment by credit card at this time. You may pay at the door. Please register on the web page www.GGPF.org

Topic Description Biology self-assembles structures with nanoscale precision that can grow, adapt to their environment, and even self-replicate. These complex behaviors are the result of complex networks of chemical reactions consisting of hundreds or even thousands of proteins, lipids, and nucleic acids with particular concentrations and reaction rates.

While building synthetic networks is still out of reach, we can explore complex self- assembly using synthetic DNA. DNA's well-understood chemistry and sequence-specific chemical interfaces allow us to "program" self-assembly reactions with many components that yield predictable results. Dynamic cascades of reactions can be organized by building metastable structures and controlling access to catalysts and molecular fuel that can drive changes in form.

We can use DNA to build not just double helices, but branched 2- and 3-dimensional structures, nanotubes, and other polymers shapes. These structures can serve as "nanobreadboards" with complex patterns that can serve as templates for nanoparticles or proteins. Further, we can start to think about assembling these structures in complex geometries. As an example, I'll talk about building scaffolds for self-guiding wires, i.e. the self-assembly of nanotubes between two terminals where the locations of the end points are uncertain.

************************************************************ Fogarty Lecture, Friday Afternoon, Oct. 15, 2010

Topic: “Have We Reached the End of Healthcare Innovation?” Speaker: Schramm, CEO of the Kauffman Foundation for Entrepreneurship Date and Time: October 15, 2010 3:30 – 6:00 PM Location: Clark Center Auditorium, 318 Campus Drive, Stanford University Cost: Free See details at http://biodesign.stanford.edu/bdn/networking/fogartylectures.jsp

**************************************************************** Biotech Bay Career Fair, Monday Afternoon, Oct. 18, 2010

Date and Time: Monday, October 18, 2010, 2pm to 7pm Location: San Francisco Airport Marriott

Biotech * Pharmaceutical * Medical Device & Diagnostics To register go to http://www.biospace.com/jobs/career-fair-detail/?CareerFairId=202

Looking for a new job? Networking with industry peers in an ever-changing work environment? Attend the Biotech Bay Career Fair! Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Bay area.

Who should attend? Candidates with a 4-year degree in the life sciences and a minimum of 2-years of industry related experience are invited to attend. Just register by clicking the button below.

(Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.)

What types of positions are available? Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research.

What companies will be there? Scroll to the bottom of the pages to see a list of exhibiting companies. Take the time to research what each company is recruiting for to see if you are a match. Most companies will be from the Bay area, but some will travel from other regions to attract top talent! If you can’t make it on event day, you can still pre-register online to allow exhibiting companies to view your resume and contact you outside of the career fair. Want to hire candidates at this event? ****************************************************************

FountainBlue's Life Science Entrepreneurs' Forum, Monday Evening, Oct. 18, 2010

Topic: “Software Meets Healthcare: Forging the Win-for-All” Facilitator Soody Tronson, Soody Tronson Law Group

Panelist Melissa Karr, Vice President, Marketing, Brain Resource, Ltd Panelist Sunil Maulik, Board Adviser, Health 2.0; Senior VP, Business Development, People Power Company Panelist John Steuart, Managing Director, Claremont Creek VenturesPresenting Entrepreneur Ash Damle, Founder and CEO, Medgle Date & Time: Monday, October 18 from 5:30 to 7:30 p.m. Location: UCSC Extension, 2505 Augustine, Santa Clara Member Registration: $22, through http://fountainblue.shuttlepod.org/ by September 24 at noon Partner and General Registration: $32 - $42, through October 15 at noon using the PayPal link at http://www.svlifescience.com.

On-Site Registration Cost: $42 members, $52 non-members, $124 Ongoing membership plus admission

Audience: Life Science entrepreneurs, intrapreneurs and investors; no service providers please

Speaker Bios Soody Tronson, principal and founder of Soody Tronson Law Group, is a seasoned professional with over 20 years of experience combining law, science, engineering, and business management in start-ups and established environments. Soody practiced law as IP Counsel at Silicon Valley offices of prominent national law firms and in-house at the Hewlett-Packard Company. Soody was General Counsel and Vice President of Intellectual Property at a successfully acquired medical device start up company where she was responsible for all legal matters including clinical trials, corporate transactions (e.g., acquisition, merger), licensing and partnering transactions, employment issues; and played a key role in the development of strategies for dispute resolution and litigation. Before starting her legal career, she spent several years in the industry holding technical and management positions at companies such as Hewlett-Packard and Schering-Plough. Her extensive experience enables the patent and transactional counseling of clients in the areas of life sciences, medical devices, and high technology. Based on the range of her experience and founder of two companies, she is well accustomed to challenges facing emerging as well as mature companies. Soody serves in Of Counsel capacity with other firms and consults with several companies. She is on the advisory board of several organizations including, the Silicon Valley Chapter of the Licensing Executives Society (LES) and the Association for the Sports and Athlete Professionals. She instructs courses in IP and licensing at the University of California. She serves as a mentor at the Stanford Technology Venture Formation Program, is an advisor with Astia, and volunteers her services at local non- profit organizations. She is also an inventor on patent applications and issued patents. Soody holds a J.D. and M.S.; and is licensed to practice before the State of California and the U.S. Patent and Trademark Office.

Melissa Karr has extensive international advertising and marketing experience, and integrates customer insights, brand strategy and marketing communications skills in her role as VP of Marketing for Brain Resource, Ltd. Brain Resource has established the first and largest human brain database to make sense of the brain's complexities and provide a coherent model for measuring brain health. Prior to joining Brain Resource, Mrs. Karr served as account management with Young and Rubicam Advertising in the US and Europe, the Executive Director for the American Chamber of Commerce in Vietnam and as a marketing consultant to numerous life sciences start-ups. She received a BS in Marketing from Miami University and an MBA from Wayne State University.

Dr. Sunil Maulik has over twenty years of sales and business development experience in Silicon Valley. He has co-founded three companies, including MonetaSuite, a business analytics company focused on email activity; RemakeHealth, a healthcare-IT company; and GeneEd, a provider of e-learning solutions. In addition, he has held senior sales and management positions at Pangea Systems, Tripos, Hoffmann-La Roche, Oxford Molecular and IntelliGenetics. Sunil also participates in several non-profit ventures dedicated to improving health in sustainable communities, including Health2.0, the Pacific AIDS Education Center and Project Ahimsa. He is enthralled by the opportunity to create energy-sustainable communities by encouraging people to go green.

John has spent the last 20 years managing, building and investing in technology and life science companies. John focuses on the intersection of the information technology and life sciences markets including bioinformatics, molecular diagnostics, genomics, proteomics, software and instrumentation for med-tech industries. John serves on the board of directors of Arcxis, Tibion, Fluxion, Gene Security Network and Wired Benefits. He is an Industry Fellow at the Center for Entrepreneurship and Technology at the College of Engineering as well as a member of the Advisory Council to the Lester Center's Berkeley Entrepreneurs' Forum at UC Berkeley. Early in his career, he joined Alafi Capital, an Emeryville-based venture firm specializing in early-stage biomedical companies, where he served as an officer of the General Partner. At Alafi, John lead investments in more than a dozen successful start-ups, and served as the senior executive and board member of various firms such as Tanox, Software Ventures, Lipomatrix and Megan Health. In the mid-90s, together with colleague Nat Goldhaber, John helped start Cybergold, an Internet marketing and payments company, serving as the early COO and CFO through its IPO, merger with Mypoints and sale to United Airlines. John continued with the Mypoints unit of United serving as the Senior Vice President of Strategic Partnerships.

John lives in Berkeley with his wife and three children, a block away from the Triple Rock brewery. Throughout his career, Ash Damle has applied practical artificial intelligence (AI) with his work at MIT, Navy, California Department of Corrections and Rehabilitation, and Jcrew. Now, as founder and CEO of Medgle, Ash believes that the information revolution has changed the very fabric of society and is positioning Medgle to address the next stage of the i-revolution by facilitating the democratization of knowledge and expertise by empowering healers with the data and resources to better support their patients, and patients to better support themselves.

******************************************************************* Bio2Device Group, Tuesday Morning, Oct. 19, 2010

Topic: “New Frontiers for Aerosol Development: The Pulmonary Infusion Pump” Speaker: James B. Fink, PhD, RRT, FAARC, FCCP, Chief Clinical Officer, LLC Consultant, Scientific Advisor Aerogen, Adj. Prof. Georia State Univ. Date and Time: Tuesday, Oct. 19, 2010, 8:30 – 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Street and in NOVA and library parking lots across the street.

Topic Description Medical aerosol development has radically transformed over the last 50 years. To date, every aerosol drug/device combination has been approved for the treatment of ambulatory patients with moderate disease, with systems with inhaled dose efficiency of 10 - 20% of dose. When patients suffer severe exacerbation of the pulmonary disease, approved devices are less effective, and clinicians are faced with the challenge of administering these vital medications, often requiring different dosing and delivery strategies.

Prior to the turn of this century, aerosol delivery to critically ill patients was limited to single digit deposition efficiency with huge interpatient variability. New technologies have opened the door to deposition efficiencies between 10 - 60% to infants and adults in the ICU, reducing variability and making development of inhaled drugs a viable option.

As learned from the inhaled insulin experience, no matter how ill fated, inhalation is second only to intravenous route for speed for both systemic and local pulmonary delivery. Methods of precision drop by drop nebulization has opened the opportunity for precise dosing control, second only to IV administration in terms of speed and accuracy.

Drug development for patients in the ICU has potential to fill great patient needs while reducing some of the cost and time barriers associated with ambulatory care of chronic pulmonary disease. Most ventilated patients are in the ICU for less than 11 days, reducing the active treatment and followup time requirements and single doses of drug in the ICU may command reimbursement associated with a month of therapy for treatment of asthma or COPD. Shorter development times and higher revenue per dose has made development of aerosol drug device combination for the ICU an attractive drug development opportunity.

Speaker Bio Dr. Fink is a Registered Respiratory Therapist with Neonatal Pediatric Specialty Certification with the National Board for Respiratory Care, with a PhD in Pharmaceutical Innovation from Bradford University, UK and a Fellow of both the American Association of Respiratory Care (FAARC) and the College of Chest Physicians (FCCP). Jim was Director of Respiratory Programs at Aerogen in 2000, with 30+ years of experience in clinical and academic respiratory care as a clinician, manager, administrator, educator and researcher. As Fellow of Aerosol Science with Aerogen (and later Nektar), Jim was key to the development of high efficiency aerosol delivery systems for use with adults, children and infants in both critical care and ambulatory settings, with multiple US and international patents. Jim was Technical Director of Respiratory Care at University of California, San Francisco for 14 years and developed a medical aerosol research lab emphasizing aerosol delivery to critically ill patients at Hines VA Hospital and Loyola Stritch School of Medicine, Chicago. Jim is an internationally recognized researcher and lecturer authoring 3 textbooks, >40 chapters and >70 peer reviewed papers. Jim is currently an Adjunct Professor for the Respiratory Therapy Program at GA State University and serves on the editorial board for the Journal of Aerosol Medicine and Pulmonary Drug Delivery and the Board of Director for the International Society of Aerosol Medicine. Since 2003, Jim has worked as the primary interface with the Measles Aerosol Vaccine initiative of the WHO, and is actively involved in developing liquid aerosol delivery systems for mass campaigns in the third world.

************************************************************* Bioscience Forum, Wednesday Evening, Oct. 20, 2010

Speaker: Donald Francis, M.D., D.Sc, Executive Director, Global Solutions for Infectious Diseases Topic: "Vaccines for Less Developed Country Diseases: A New Era for Discovery and Development" Date and Time: Wednesday, October 20, 2010 6:00 PM - 9:00 PM 6:00 pm - 7 pm networking 7:00 pm - 8 pm dinner 8:00 pm - 9 pm presentation Location: The Clarion Hotel, 401 East Millbrae Avenue, Millbrae Full info and Registration at: http://biosf.org/ Cost: $45 before 9:00 PM, Monday, Oct. 18 $55 on-site $35 full-time students pre-registration $45 full-time students on-site $3 service fees will be added to the pre-registration prices Pre-Registration ends Monday, Oct. 18, at 9 pm Cash or check accepted on the day of the event Parking is $2 Review Event Summary and Register at: http://www.cvent.com/EVENTS/Info/Summary.aspx?i=a3314109-a5c4-40c7-a7d5- 8fef6ebe362b Cash or check accepted on the day of the eventParking is $2 Or you can pay with a check made out to "BioScience Forum" and sent to: BioScience Forum 1442A Walnut Street, #308 Berkeley, CA 94709-1405 Please do not mail checks later than Thursday, October 14th If paying with check, do not complete online registration with Cvent

Topic Description Vaccines, the predominant tool used to prevent worldwide infectious diseases, are a challenge to develop and bring to market. Recent funding from large not-for-profit institutions has stimulated a new era in vaccine development – especially for less developed country diseases. The funding has produced a new wave of vaccine discovery, actual product development and, ultimately, delivery to at-risk children. Not only have the children in less developed countries been the recipient of these vaccines, but more and more of both the development and manufacture of these important products is taking place outside of Europe and North America. BiographyAs an infectious disease trained pediatrician and epidemiologist, Dr. Francis has over 30 years experience in epidemic control and vaccines. He spent 21 years working for the U.S. Centers for Disease Control (CDC) focusing on vaccine-preventable diseases such as measles, cholera, smallpox, and hepatitis B. He directed the WHO’s Smallpox Eradication Program in Sudan and U.P. State in Northern India. His hepatitis B vaccine work included Phase III trials among gay men in the United States and among infants born to carrier mothers in China. Dr. Francis was also a member of the WHO team investigating the world’s first outbreak of Ebola virus in 1976.

Speaker Bio Dr. Francis has worked on HIV/AIDS since its emergence in 1981. He initially directed the AIDS laboratory at the CDC and worked closely with the Institut Pasteur to identify the causative virus. His early efforts to call attention to the threat of AIDS and warn of the inadequacy of the public health response were chronicled in the movie And the Band Played On. In 1992, he joined Genentech to spend full time developing vaccines, while he also helped found what became the International AIDS Vaccine Initiative (IAVI). With waning private sector interest in HIV vaccine development, Dr. Francis co-founded VaxGen, which completed the world’s first Phase III trials of two candidate HIV vaccines in 2003. In early 2004, he left VaxGen to co-found GSID with Carter Lee and Phil Berman.

**************************************************************** IEEE, Engineering in Medicine and Biology Society, Wednesday Evening, Oct. 20, 2010

Topic: INFocus Coherent Image Formation Technology Speaker: Wilko Wilkening, PhD, Siemens Medical Solutions USA, Inc. Date and Time: Wednesday, October 20, 2010, 7:30 pm Location: Room M-114, Stanford University Medical School Optional dinner location change: Stanford Hospital Cafeteria, 6:15 pm (no host, no reservations)

Topic Description INFocus is a real-time Coherent Image Formation technology that provides dynamic transmit focusing at every pixel. All conventional digital receive beamformers provide dynamic receive focusing through delay profiles that vary dynamically tracking the depth from which the echo is received. But the transmit focusing has been static, and it has been limited to a single or a couple of discrete focal depths for decades. With the introduction of INFocus, dynamic receive focusing is complemented by dynamic transmit focusing which completes the round-trip dynamic focusing throughout the image. This improves detail resolution, contrast resolution, SNR and frame/volume rate. INFocus is similar to synthetic aperture imaging in that information from different parts of the transmit aperture are contributed by separate pulse-echo events. This set of information is combined in a phase-sensitive, i.e., coherent manner, retrospectively after the receive beamformation. There are however three differences between INFocus and conventional synthetic aperture. First the component acquisitions use full transmit and receive apertures as opposed to single element or small apertures. Secondly the data is combined in a depth dependent manner that provides transmit focus at all depths. And lastly a progressive acquisition scheme is used so that frame rate is preserved and even improved, not reduced. This capability is enabled on the SC2000 by a digital receive beamformer that has massive parallel beamformation capability and a Coherent Imageformer that has proprietary architecture and super processing bandwidth.

Speaker Bio Dr.-Ing. Wilko G. Wilkening (IEEE member since ’97) was born in Bonn, Germany in 1970. He received his Master’s degree (Diplom-Ingenieur) in 1995 and his PhD (Doktor- Ingenieur) in 2003 in Electrical Engineering from the Ruhr-Universität Bochum, in Bochum, Germany. Dr. Wilko Wilkening is currently a staff systems engineer at Siemens Medical Solution USA, Inc., Mountain View, CA where he contributes to the development of real-time 3D ultrasound systems for medical imaging. During a yearlong internship in 1996 in the Advanced Development Department of Siemens Medical Systems, Inc., Ultrasound Group, Issaquah WA, USA, he participated in the early developments of 3D and contrast ultrasound. While working towards his PhD under the supervision of Prof. Helmut Ermert, he further pursued research on ultrasound contrast imaging. Other research interests include beam forming and flow imaging. From 2004 to 2008, he worked for Krohne Messtechnik GmbH & Co. KG performing research on ultrasonic flowmeters. He received the "Young Investigator Award" at the Fifth Heart Centre European Symposium on Ultrasound Contrast Imaging in 2000, and in 2003 he was awarded the "Gebrüder Eickhoff-Preis" for his PhD thesis.

***************************************************************** BayBio Therapeutic Focus, Thursday Early Evening, Oct. 21, 2010

Topic: “Therapeutic Focus | Drug and Biomarker Developments: The Evolution of Blockbusters?” Speakers: Panel Moderator: Michael J. Shuster, PhD, Partner, Fenwick & West LLP; Panel Speaker: Rowan Chapman, Partner, Mohr Davidow Ventures and Mitch Raponi PhD, Sr. Director Molecular Diagnostics, Clovis Oncology Date and Time: Thursday, October 21, 2010 Registration Opens: 3:30pm Panel Presentation: 4:00pm - 5:30pm Networking Reception: 5:30pm - 6:30pm Location: South San Francisco Conference Center, 255 South Airport Blvd., South San Francisco, CA Pre-registration through October 19 $20 BayBio Members | $40 Non-Members On-site registration on October 21 $40 BayBio Members | $75 Non-Members Attire: Business attire suggested See details for registration at www.BayBio.org. You must register on website to access. You can register as guest.

Topic Description The promise of personalized medicine has begun to be realized with several commercially successful products, notably Herceptin, Gleevec, and Rituxan that all rival conventional "blockbusters." Higher rates of efficacy and more efficient (and therefore cost effective) trials have made products based on biomarkers increasingly intriguing and attractive to an industry chronically beset with R&D failures. Should we expect life science and pharma companies to embrace the biomarker strategy as their primary business model, or will biomarker-derived products remain a niche market? And should diagnostics be developed in tandem with pharmaceuticals or independently? A panel of experienced industry executives will focus on the real world experiences and will provide valuable insight into business and regulatory landscape surrounding biomarker technology. ************************************************************** 2010 Professional Dinner Meeting Series, Thursday Evening, Oct. 21, 2010

Topic: "Member Appreciation Night - Fermentation, Recovery, & Quality Control" Tour & Networking Social Date and Time: October 21, 2010 | 6:00-9:0 PM Location: Pyramid Alehouse Mezzanine, Berkeley CA

Topic Description PDA's West Coast Chapter is pleased to have its 2010 Member Appreciation Night in the East Bay at the Pyramid Alehouse in Berkeley, just a few miles from the University of California campus. We will have a guided tour of the facility, learn about the process, perform some non-routine taste sampling, and have some lively discussion around fermentation, recovery and quality control. We hope that you can join us! Registration Information $10/Person includes tour, appetizers & beverages. Cash or check at the door only. Please do not use PayPal for this event!

Submit advance registration requests via e-mail to [email protected] with "WCC PDA October 2010 Event RSVP" as the subject line. Indicate name and company affiliation for each registrant. Reserved seating is limited to the first 100 registrants! It is strongly encouraged that you register in advance to ensure seating at this event, and to allow us to provide an accurate head count for the tour. Parking is available on-site.

Cancellation Policy Dinner seating is confirmed and reserved in advance. We regret that no refunds can be offered for non- attendance. If a registrant cannot attend, substitutions are welcome. ******************************************************************

Silicon Valley Quality Conference, Thursday-Friday All Day, Oct. 21-22, 2010

Description: ASQ Convention has general quality focus across industries with one track out of 4 tracks focused on biotechnology this year: • ISO 13485:2003 the Standard and its Compliant Implementation • Implementation of Risk Management in the Medical Device Industry • Value Added Audits • Risk Management of Medical Devices • Meeting the New MDD Requirements for Medical Device Software Development – ANSI / AMI / IEC 62304

Date and Time: Thursday, Oct. 21, 2010 - Friday, Oct. 22, 2010,7:30 AM - 5:30 PMLocation: Network Meeting Center at Techmart, 5201 Great America Parkway, Santa Clara, CA 95052 Non ASQ Member Pricing $300.00 - Regular pricing starts 10/2/2010 $400.00 - List pricing starts 10/18/2010 But pricing varies according to membership and employment status See details at http://www.asq-silicon-valley.org/

***************************************************************** 2010 RAPS Annual Conference & Exhibition in San Jose, Sunday – Wednesday, Oct. 24-27, 2010

Topic: “Succeed in the Global Regulatory Environment” Dates: Sunday-Wednesday, Oct. 24-27, 2010 Location: San Jose McEnery Convention Center, San Jose, CA Find full details at http://www.raps.org/personifyebusiness/ Event Description Don’t miss the most globally representative conference RAPS has ever convened. Attendees will hear from more than 50 top officials from regulatory agencies around the world, including: . US Food and Drug Administration (FDA) . US Department of Justice (DOJ) . European Medicines Agency (EMA) . State Food and Drug Administration (SFDA), China . Pharmaceuticals and Medical Devices Agency (PMDA), Japan . Ministry of Health, Labour and Welfare (MHLW), Japan . Korea Food and Drug Administration (KFDA) . National Health Surveillance Agency (Anvisa), Brazil . Department of Biotechnology, Ministry of Science and Technology, India . Ministry of Health, Welfare and Sport, The Netherlands . Health Canada Fee: RAPS Member $1,230; nonmember $1,415. Thursday, 30 September is the last day to register for at the special advance rate (save $150) on your full conference registration! See details about special rates at http://www.raps.org/PersonifyEbusiness/Default.aspx?TabId=1604

******************************************************************* RAPS Conference Exhibitor Reception, Monday Evening, Oct. 25, 2010 Event: Exhibitor Reception and Wine Tasting at RAPS 2010

Date and Time: 25 October 2010, 5:00–6:00 pm Location: San Jose McEnery Convention Center,Santa Jose, CA Cost: $25 Even if you are unable to participate in the RAPS Annual Conference & Exhibition from Oct. 24-27 this year, RAPS, the SF Chapter invites you to attend the Exhibitor Reception and Wine Tasting on Monday, 25 October, from 5:00–6:00 pm, a special $25 rate. This special event pass includes:  Exclusive access to a premier networking event at 2010 RAPS, to include regulatory professionals and thought leaders from around the world as well as representatives from more than 100 companies on the leading edge of technology  One free drink ticket  Full access to the wine tasting, featuring a selection of wines from Napa Valley and Sonoma County accompanied by an assortment of cheese; William Hill and Louis Martini wineries will be represented Register at http://www.raps.org/personifyebusiness/tabid/55/Default.aspx?ProductId=6713 ******************************************************************* Windhover PharmAsia Summit 2010, Monday and Tuesday, Oct. 25-26, 2010

Topic: Taking the Risk Out of Asia: Top Pharma Leaders Share Best Practices-- the most strategic-level meeting where senior biotech and pharma executives share real-life case studies on how they're building a presence in Asia - from drug development to market. Date and Time: October 25-26, 2010 Location: InterContinental Mark Hopkins, San Francisco www.windhover.com/PharmAsiaSummit Cost: $200 Discount until September 30, 2010 Full Price after September 30, 2010 Standard Registration: 1st and 2nd attendee* $1495 ($200 savings) Includes:  Entrance to all sessions.  Admission to cocktail receptions and all breakfasts/lunches/breaks.  Conference materials, proceedings booklet, and copies of presentation slides, as permitted. 15% off any Elsevier Business Intelligence products purchased at the event. Dealmaker’s Package: 1st and 2nd attendee* $1995 ($350 savings) Includes:  2 nights hotel room & taxes and Recordings of sessions in addition to standard registration included *3rd free - Attendee provides hotel accommodation Early Bird Registration Ends Sept. 30th so register today! Convenient online registration is available http://www.windhover.com/windhover/content/conferences/pasreg.htm?&utm_campaig n=PAS10 or contact Pat Cardone at [email protected] or 203.838.4401x124.

Topic Description This year's PharmAsia Summit brings Asian, US and European industry leaders to San Francisco to share their experiences and help those already involved in Asian operations or planning Asia strategies to better understand the myriad of complex challenges and equally attractive opportunities facing them. Here's what you get from this year's PharmAsia Summit:  Merck's emerging markets strategy through acquisition vs. organic growth  5+ opinions on where to place your bets and how to hedge risks when investing in Asia  38+ perspectives from Asia investors, corporate executives and regulators  4+ regulator presentations from US, China, and Korea FDA  11+ networking opportunities with the most senior level executives  Lessons learned on how to overcome marketing authorization, pricing and market access issues when commercializing your drug in Asia Further details on top speakers and topics can be found online at www.windhover.com/PharmAsiaSummit.

*************************************************************** Bio2Device Group, Tuesday Morning, Oct. 26, 2010

Topic: A Clairvoyante Speaks: Electronic Communication in the Health Care Arena Speaker: Candice Brown Elliott, CEO and Chief Technologist, Nouvoyance Date and Time: Tuesday, Oct. 19, 2010, 8:30 – 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Street and in NOVA and library parking lots across the street.

Speaker Bio Candice Brown Elliott is an internationally recognized leader, entrepreneur, manager, and technologist/inventor in the flat panel display and microelectronic industries. She is a featured business leader on 50Lessons.com. She is a regularly invited speaker at international conferences, industry symposia, and universities. She has held engineering and managerial posts in leading semiconductor firms as well as start-up ventures. She has founded several technology companies and led industry research consortia programs. She has 50 issued US patents, with many more pending. She has a dual degree in physics and psychology, and minored in biology. Like so many other entrepreneurs, she is a drop-out from Stanford University Graduate School. In her over thirty five year career, she has served in nearly every capacity from Department Secretary up to CEO / Chairman of the Board.

*************************************************************** Juvenile Diabetes Research Foundation & Stanford Medical School, Wednesday Lunchtime, Oct. 27, 2010

Topic: “JDRF Annual Silicon Valley Summit | Discovery to Development: Pathways for Advancing and Financing New Therapies” Panelists include:  Karin Hehenberger, M.D., Ph.D., Senior Vice President, Strategic Alliances for the Juvenile Diabetes Research Foundation  Daria Mochly-Rosen, Ph.D., Senior Associate Dean for Research & the George D. Smith Professor in Translational Medicine, Stanford University  Beth Seidenberg M.D., Partner, Kleiner Perkins Caufield & Byers  PJ Utz, M.D., Co-Founder and Consultant, Bayhill Therapeutics

Date and Time: Wednesday, Oct. 27, 11:30 am to 1:30 pm Location: Rosewood Sand Hill Hotel, 2825 Sand Hill Road, Menlo Park, CA Cost: $200/person Registration: 11:00 a.m. Register for the Summit: Contact Caroline Kinsey at (415) 597-6314

Topic Description Please join us for this ground-breaking summit featuring four perspectives on translational medicine, innovation and industry brought to you by the Juvenile Diabetes Research Foundation (JDRF) in association with the Stanford School of Medicine. In Menlo Park. Detailed Information contact [email protected] rg

************************************************************** Palo Alto AWIS, Wednesday Evening, Oct. 27, 2010

Topic: “Next Generation Sequencing: Shedding Light on Human Evolution and Disease” Speaker: Fiona Hyland Date and Time: Wednesday, October 27th, 2010; 7.00PM-9.00PM Location: PARC Auditorium, 3333 Coyote Hill Road, Palo Alto, CA-94034 Cost: $5 for Palo Alto AWIS members and students, $10 for non-members

***************************************************************** San Jose Biocenter, Thursday Mid-Day, Oct. 28, 2010

Topic: “Startup in a Box: Efficient Operations Management” Speakers Brian Hassan, Managing Director, BAYPOINT BENEFITS Justin Roberts, Managing Director, BAYPOINT BENEFITS Olga Karobkoff, CEO (Interim CFO for Start-ups), ACCUSTART Date and Time: Thursday, October 28, 2010, 11:30am-1:00pm Agenda 11:30am-12:00pm: Registration & Networking 12:00pm-1:00pm: Presentation and Q&A Location: San Jose BioCenter, 5941 Optical Court, Second Floor. San Jose, CA 95138 Cost: Regular Price: $25 • Partners' Network: $15 • BioCenter Members: Free (please RSVP to Melissa) • On-site Registration: add $10 to the above. This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day! Register at http://startupinaboxsjbc.eventbrite.com/ Topic Description With increased pressure to deliver value efficiently and effectively, startups need all the help they can get. Accurate, comprehensive operational management from the start is a crucial first step to the success of any business. Join us for one hour interactive session on how you can best manage your operations resulting in maximum time spent on value creation and minimum time spent on maintaining the back-end. In this session, you will learn the key steps to ensure every facet of your new business runs smoothly from finance, accounting, HR, legal/contracts, facilities management, general administration, and more. Who Should Attend:  Founders/entrepreneurs raising funding  Newly founded corporation overwhelmed with operational requirements  Rapidly growing young company looking for direction and assistance but isn't ready for a CFO  A business in need of a capital lease line or banking/cash management options  A small business requiring short-term support such as budget planning, audit preparation, finding office space, or preparation for lay-offs  A foreign company establishing an office in the U.S. ************************************************************* GABA, Thursday Evening, Oct. 28, 2010

Topic: Cancer Causation by Infections Speaker: Dr. Harald zur Hausen, professor emeritus at the University of Heidelberg Date and Time: Thursday, Oct. 28, 2010, 5:30-8:00 pm Location: Duane Morris LLP,One Market Plaza , Spear Tower,Suite 2200 San Francisco, CA Cost: $20 members; $35 Non-members, $50 at the door Register at https://s07.123signup.com/servlet/SignUp?PG=1532265182300&P=1532265191142148 0700&Info= Seating is extremely limited. Please register by Friday, October 22, 2010!

Topic Description Please join Duane Morris, Heidelberg Club International, Heidelberg Technology Park and the German American Business Association for a Seminar by 2008 Nobel Laureate Prof. Dr. Harald zur Hausen.

About 20 percent of global cancer incidences are caused by infectious agents, including viruses, bacteria and parasites. Prof. zur Hausen's talk analyzes the discovery of these cancer causes and highlights epidemiological observations of additional infectious agents in specific human cancers. Emphasis will be placed on the role of papillomaviruses in human cancers and his research leading to the development of protective vaccines.

Speaker Bio: Prof. Dr. Harald zur Hausen is professor emeritus at the University of Heidelberg. From 1983 until 2003, he chaired the scientific advisory board of the German Cancer Research Center (Deutsches Krebsforschungszentrum) in Heidelberg. In 2008, Professor zur Hausen was awarded the Nobel Prize in Medicine for his research on cancer of the cervix, and his discovery of the role of papillomaviruses in its cause. Complimentary appetizers, beer, wine and soft drinks will be served. *********************************************************** 2010 CBA Annual Conference, Saturday Afternoon & Evening, Oct. 30, 2010

Overall Topic: “A Sea Change: Advancement in Biotech & Pharmaceutical Industry” Individual Topics:

 Therapeutic Drug Development  Biomarkers and Diagnostics  Personalized Medicine  Career and Business Opportunities See full program with speakers and registration costs at http://www.cbasf.org/pages/2010acagenda Date & Time: Saturday, October 30 2010, 1:00 – 9:00 pm Conference: 1:00 – 6:00 pm Banquet Dinner: 6:45 – 9:00 pm (with live entertainment & keynote) Location: DoubleTree Hotel San Jose, 2050 Gateway Place, San Jose, CA 95110

Read more: CBA - Biotech, Life Science Organization in Bay Area, California - Chinese Bioscience Association in San Francisco

******************************************************** Bio2Device Group, Tuesday Morning, Nov. 2, 2010

Topic: TBA Speaker: TBA Date and Time: Tuesday, Nov. 2, 2010, 8:30 – 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Street and in NOVA and library parking lots across the street.

******************************************************************* California Healthcare Institute, Monday, Nov. 8, 2010

Topic: Keeping Pace with Technology: Diagnostics Regulation Date and Time: Monday, November 08, 2010 11:30 AM - 6:00 PM (Pacific Time) Agenda-at-a-Glance 10:00 - 11:30 a.m. CHI Dx Working Group Meeting (Closed to DxWG Members Only) 11:00 - 11:30 a.m. Conference Registration 11:30 a.m - 1:00 p.m. Luncheon Keynote Speaker - Paul Brown, President and CEO, Roche Molecular Systems, Inc. 1:00 - 1:30 p.m. Policy Perspective: Regulation of Laboratory Developed Tests 1:30 - 3:00 p.m. Moderated Panel Discussion Q & A - Regulation of Laboratory Developed Tests 3:00 - 3:30 p.m. - BREAK 3:30 - 4:30 p.m. Moderated Panel Discussion Q & A - Regulation of Gene Sequencing Moderator: Greg Heath, Ph.D., SVP and General Manager, Diagnostics, Illumina, Inc. 4:30 - 5:00 p.m. Keynote Speaker - Peter Maag, President, Novartis Diagnostics 5:00 - 6:00 p.m. Closing Reception Location: Roche Molecular Systems, Inc.,4300 Hacienda Drive,Pleasanton, California 94588,Phone: 8585516677, Email: [email protected] Cost: BayBio member rate is $100. Nonmembers,$150 In Pleasanton. Detailed Information at http://www.regonline.com/register/checkin.aspx?EventId=892412

Topic Description The diagnostics industry is changing rapidly, fueled by basic scientific advances in genomics and molecular genetics, along with technological innovations in areas like gene sequencing. It's clear that policy and regulation have not kept pace with this fast- moving field. To build a better understanding of the complex regulatory and political environment surrounding diagnostics, and to refine our advocacy agenda, CHI is organizing a half-day forum. It will bring together industry executives, government policymakers and regulators, as well as policy experts to discuss topics such as regulation of laboratory-developed tests, the dynamic changes in FDA's 510(k) process, regulatory approaches to sequencing and other vital topics. Register now to participate in this timely event.

***************************************************************** Bio2Device Group, Tuesday Evening, Nov. 9, 2010

Topic: “Overcoming Challenges Common to Biotech Start-Ups” Speaker: Lubna Ahmad, PhD, Founder & CEO, Invoy Technologies Location: Wilson Sonsini Goodrich & Rosati-- 650 Page Mill Road, Palo Alto , CA 94306 Register at www.bio2devicegroup.org week prior to meeting Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins

Topic Description This presentation will describe challenges associated with early stage medical device companies, including implementing a quality system, obtaining investment capital, fostering in-house innovation, and recruiting a management team.

Speaker Bio Lubna Ahmad, PhD, Founder & CEO, Invoy Technologies, LLC (www.invoy.com). Dr. Ahmad has spent nearly a decade innovating and developing medical devices with an emphasis on biosensor technologies. She founded Invoy to commercialize and build upon her novel designs. Having recruited an experienced and diversified team and raising necessary investment capital, Dr. Ahmad has managed the company through the development phase, executed a series of partnerships and intellectual property transactions, and positioned the company for product launch. Her experiences in sensor development and clinical study protocol design have been key in Invoy’s ability to successfully execute a demanding product development program. Dr. Ahmad also serves as an advisor to a molecular diagnostics company and is a frequent presenter at biotechnology seminars and conferences. Prior to founding Invoy, Dr. Ahmad was a fellow of the National Science Foundation. Dr. Ahmad holds a PhD in biomedical engineering from Arizona State University where she was a Goldwater Scholar. ***********************************************************

BIOMEDevice 2010 San Jose, Wednesday – Thursday, Nov. 10-11, 2010

Dates and Time: Wed. starting at 8:30 am-Thursday, 5:00 pm, November 10-11, 2010 Location: San Jose McEnery Convention Center See fees and registration at http://www.canontradeshows.com/expo/biomed10/conference.html

Conference description Join innovators and industry leaders at this year’s BIOMEDevice Forum as they share in- depth knowledge on topics critical to next-generation technologies. The forum will examine the most timely and critical issues surrounding enabling technology for R&D, product development, design, engineering, and regulatory affairs professionals within the medical device industry. The forum is designed to provide medical technology executives the information they need to stay ahead of their competition through a series of keynote presentations, case studies, and high-level technology sessions within the following sector specific areas of: Cardiovascular, Neurotechnology, Healthcare Reform, and Innovation & Connectivity.

Who Should Attend:

Medtech professionals with responsibilities within Engineering, Manufacturing, Product Development, Quality, Regulatory Affairs, and Research & Development. Key Benefits of Attending: · Hear novel approaches to the diagnosis and treatment of brain and nervous system disorder created through rapidly evolving technology. · Discuss the good tenets of cardiovascular device design.Consider how the changing regulatory landscape will impact innovation in the medical device industry. · Explore the opportunities and challenges connectivity present for medical device manufacturers. · Examine the impact of healthcare reform on the future of medical technology. · Get the latest information and meaningful details in the health legislation and their ramifications for your organization. · Analyze major trends related to medical device design, engineering, commercialization, and heathcare reform.

***************************************************************

FountainBlue's Life Science Entrepreneurs' Forum, Monday Evening, Nov. 15, 2010

Topic: “Personalized Medicine, Biomarkers, Invitro Diagnostics: The Science Advances, The Business Opportunities, The Cultural Dilemmas” Date & Time: Monday, November 15 from 5:30 - 7:30 p.m. Location: Life Technologies, 850 Lincoln Centre Drive in Foster City Pre-register: $21 members, $32 partners, $42 general Late and On-Site: $42 members, $52 non-members, $124 Ongoing membership and admission Members can register at: http://fountainblue.shuttlepod.org/lifescience To Become a Member visit: http://fountainblue.shuttlepod.org/membershipapp Non-Members and Partners can register at: http://www.svlifescience.com Pre-registration Deadline: November 12 at noon

Facilitator tbd Panelist from Life Technologies, to be confirmed Panelist VC, tbd Panelist from Stanford, tbd Panelist Brandon Steele, Vice President, Commercial Operations, IncellDx, Inc. Presenting Entrepreneur Robert E. Dunkle, President and CEO, PlexPress Inc. Presenting Entrepreneur, Biomarker Presenting Entrepreneur, Invitro Diagnostics Presenting Entrepreneur, Customized Treatments Audience: Life Science entrepreneurs, intrapreneurs and investors, no service providers please For more information, visit http://www.SVLifeScience.com.

*******************************************************************

Bio2Device Group, Tuesday Morning, Nov. 16, 2010

Topic: TBA Speaker: Frank Ingle, CEO, Instruments for Science and Medicine Inc. Date and Time: Tuesday, Nov. 16, 2010, 8:30 – 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Street and in NOVA and library parking lots across the street. ********************************************************************* Bio2Device Group, Tuesday Morning, Nov. 23, 2010

No B2DG Meeting - Happy Thanksgiving **************************************************************************

Bioscience Business Development: Building Value, Thursday & Friday, Dec. 2-3, 2010

Event Topic: Bioscience Business Development: Building Value Intensive Course Sponsoring Group: UCSC Extension Date and time: Thursday and Friday, Dec. 2-3, 2010 Location: 2505 Augustine Drive, Santa Clara, CA 95053 Speaker (s):  Instructors: Audrey Erbes, Principal, Erbes & Associates and www.audreysnetwork.com and and Gilbert R. Mintz, Ph.D., President of GRM Associates  Harold (Hal) Etterman, MBA, Business Strategist  Carolyn Feamster, MBA, VP, Business Strategy & Analysis  Ginger R. Dreger, M.S.,J.D., Partner Arnold & Porter LLP  Tom Gutshall, Chairman & Co-Founder of Cepheid  Mark Edwards, Managing Director, Deloitte Recap, LLC, and Founder, Recombinant Capital  Herwig VonMorze, Ph.D., International Patent Consultant

Fees: $850.00, ($765 through Nov. 18) Registration and more Information: www.ucsc-extension.edu/biobizdev

Topic Description UCSC Extension in Silicon Valley presents a two-day intensive course that brings the breadth of the Bay Area’s biobusiness development expertise to our Santa Clara classroom. Whether financing start-up activities, trying to keep pace with the current burn rate, or moving a product into the marketplace, bioscience companies, both large and small, have a critical need for business development at every stage of their evolution. Learn the key roles that business development and licensing play in the commercialization of a new product and the development of a successful bioscience company. Santa Clara, CA. For more information, see www.ucsc-extension.edu/biobizdev ******************************************************************* Bio2Device Group, Tuesday Morning, Dec. 7, 2010

Topic: Life Scientist Applies His Knowledge to Production and Selling of Improved Poultry Feed: Learn How Biotechnology Can Provide Healthier Chickens Speaker: Robert Carter, President, CEO and Founder of Nikoya Foods Date and Time: Tuesday, Dec. 7, 2010, 8:30 – 10:30 am Location: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library) Cost: Free Street and in NOVA and library parking lots across the street.

Topic Description Robert Carter, President and CEO, will talk about the company he has founded and how he's applying biotech methods to enhance the quality and production of poultry feed to impact the quality of poultry. Learn the fascinating story of how a life scientist applies his knowledge to an important health issue via enabling the production of healthier chickens but without sacrificing the bottom line for growers.

Speaker Bio

Robert Carter, Nikoya founder and CEO, grew up on a farm where he raised chicken from he was a small boy. When he was 9 years old, Robert was responsible for growing and caring for 125 chickens. On the farm, he acquired a lot of knowledge of chickens and other farm animals. In 2001 he went to Latin America and founded Finca Nicoya and became its CEO. At Finca Nicoya, he was responsible for growing, processing, marketing, selling and distributing organic chickens from 2001-2004. During this period, Robert developed a proprietary feed for organic chickens. The feed reduced organic chicken production cycle to hormone grown chicken cycle times, reducing 14 weeks to 6 weeks cycle. He has successfully grown over 50,000 chickens with his proprietary feed. Robert’s proprietary feed reduced production costs of organic chickens by 47%, reduced production mortality from 6.5% to 3.2%, reduced feed waste by 30%. **********************************************************************

Bio2Device Group, Tuesday Morning, Dec. 21, 2010

No B2DG Meeting- Happy Holidays- Next Meeting is on Jan 4, 2011 ******************************************************************** Bio2Device Group, Tuesday Morning, Dec. 28, 2010

No B2DG Meeting- Happy Holidays- Next Meeting is on Jan 4, 2011 *******************************************************************